ZOMDF 8-K
Zomedica Corp. (ZOMDF)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter) |
_______________________________
Alberta, |
|
| N/A | |
(State or Other Jurisdiction of Incorporation) |
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a Material Definitive Agreement.
On May 10, 2023, Zomedica, Inc., a wholly-owned subsidiary of Zomedica Corp., entered into an amendment (the “Lease Amendment”) to the Multi-Tenant Industrial Triple Net Lease with an effective date of March 18, 2022 (the “Lease”) by and between ULF Northfield Business Center LLC (the “Landlord”) and Zomedica, Inc. for property located at 4000 Northfield Way, Roswell, GA 30076 (the “Leased Premises”). The Amendment expands the Leased Premises by 6,000 rentable square feet (the “Expansion Premises”) from 12,400 rentable square feet (the “Existing Premises”) and extends the lease term from the date ending April 30, 2027 to a date ending sixty months after the earlier of (i) the date the Landlord delivers the Expansion Premises to Zomedica, Inc. and (ii) December 1, 2023.
As a result of the Amendment, the rent obligations increase over the term of the Lease, as amended, for the Existing Premises as follows:
Period (Measured from Expansion Date) |
| Annual Rate/RSF |
|
| Monthly Base Rent |
| ||
05/01/2027 – Month 48 |
| $ | 14.06 |
|
| $ | 14,529.49 |
|
Months 49 – 60 |
| $ | 14.62 |
|
| $ | 15,110.67 |
|
And for the Expansion Premises as follows:
Period (Measured from Expansion Date) |
| Annual Rate/RSF |
|
| Monthly Base Rent |
| ||
Months 1 – 12 |
| $ | 12.50 |
|
| $ | 6,250.00 |
|
Months 13 – 24 |
| $ | 13.00 |
|
| $ | 6,500.00 |
|
Months 25 – 36 |
| $ | 13.52 |
|
| $ | 6,760.00 |
|
Months 37 – 48 |
| $ | 14.06 |
|
| $ | 7,030.40 |
|
Months 49 – 60 |
| $ | 14.62 |
|
| $ | 7,311.62 |
|
The Amendment is furnished as Exhibit 10.1 to this current report on Form 8-K and is incorporated herein by reference. The foregoing description of the Lease Amendment does not purport to be complete and is qualified in its entirety by reference to the Lease and the Lease Amendment.
(d) | Exhibit No. |
| Description |
|
|
|
|
|
| ||
| 104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ZOMEDICA CORP. |
| |
|
|
|
|
Date: May 10, 2023 | By: | /s/ Karen L. DeHaan-Fullerton |
|
|
| Karen L. DeHaan-Fullerton |
|
|
| General Counsel and Corporate Secretary |
|
| 3 |
EXHIBIT INDEX
Exhibit No. |
| Description |
|
|
|
| ||
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 4 |
EXHIBIT 10.1
